Welcome to the Oncology Brothers podcast! In this episode we continue our series on breast cancer treatment algorithms, focusing specifically on triple negative breast cancer (TNBC). We welcomed Dr. Tiffany Traina, a breast medical oncologist from the Memorial Sloan Kettering Cancer Center, to discuss the latest advancements in the management of TNBC. We dived deep into the treatment algorithm for early-stage disease, including the criteria for adjuvant chemotherapy, the use of neoadjuvant therapies like KEYNOTE-522, and the importance of balancing risk and benefit in treatment decisions.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ Website: https://oncbrothers.com/

Key topics covered in this episode included:

* Criteria for adjuvant chemotherapy in early-stage TNBC

* The role of pembrolizumab in neoadjuvant and adjuvant settings

* Management of residual disease with capecitabine and olaparib

* Insights into the latest clinical trials, including ASCENT-03, ASCENT-04, and TROPION-Breast02

* Side effect management strategies for new therapies

Don't forget to subscribe for more episodes in our breast cancer series, and feel free to send us your questions and cases!

Listen now and stay informed on the evolving landscape of triple negative breast cancer treatment!

#TripleNegativeBreastCancer, #TNBC, #Pembrolizumab, #ADC, #OncologyBrothers